Phage Display for Improved Peptide-Based Tumor Targeting and Imaging Agents
用于改进基于肽的肿瘤靶向和成像剂的噬菌体展示
基本信息
- 批准号:10115970
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-01 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:AffinityAntibodiesAntigensBacteriophagesBindingBiological MarkersBloodBlood CirculationBreastBreast Cancer therapyCD44 geneCancer BiologyCancer DetectionCarbohydratesCell AdhesionCellsCessation of lifeChelating AgentsChemistryChemotherapy and/or radiationClinical TrialsCombined Modality TherapyComplexCoupledCyclooctenesDetectionDevelopmentDiagnosisDiseaseDoseDose-LimitingDrug KineticsDrug resistanceEstrogensExhibitsFemaleGalectin 3GenderGeneral PopulationGenomic medicineGenomicsGoalsHealthHealthcareHormonesHumanHydrophobicityImageImmune checkpoint inhibitorImmune responseImmunoglobulin FragmentsImmunologic SurveillanceIncidenceInjectionsKidneyLabelLaboratoriesLectinLigandsMalignant NeoplasmsMalignant neoplasm of prostateMammary NeoplasmsMetalsMissionMolecularMorbidity - disease rateMultimodal ImagingNeoplasm MetastasisNormal tissue morphologyNucleosome Core ParticleOrganPathway interactionsPatient CarePatientsPeptide FragmentsPeptide antibodiesPeptidesPhage DisplayPopulationProcessProgesteronePrognosisProstateProtein EngineeringRNA SplicingRadiation induced damageRadiation therapyRadioactiveRadioactivityRadiochemistryRadioimmunoconjugateRadiolabeledReactionRelapseResearchResistanceSignal PathwaySignal TransductionSilicon DioxideSurfaceT-Cell ReceptorTherapeuticTimeTissuesToxic effectTriad Acrylic ResinTumorigenicityUnited StatesVariantVeteransWomanWomen&aposs HealthWorkangiogenesisbasecancer imagingcancer stem cellcancer therapycancer typecheckpoint receptorscycloadditionerbB-2 Receptorglycosylationimaging agentimmune checkpointimmunogenicimmunoregulationimprovedin vivointerestirradiationmalignant breast neoplasmmilitary veteranmultimodalitynanoparticlenear infrared dyeneoplastic cellnoveloverexpressionprogrammed cell death protein 1radiotracerscaffoldsmall moleculestandard carestandard of carestem cell biomarkerssuccesstargeted agenttargeted imagingtargeted treatmenttheranosticstriple-negative invasive breast carcinomatumortumor growthtumorigenesistumorigenicuptake
项目摘要
Aggressive forms of cancer are a leading health problem for United States Veterans. While most cancers
are treatable in their earliest forms, gender-related cancers including those of the breast and prostate are
often fatal when diagnosed at advanced and/or metastatic stages. In 2020, these cancers will account for over
75,400 annual deaths in the general population, with morbidity rates significantly higher in the Veteran
population. While most patients initially respond to treatment, they often relapse and develop aggressive and
drug resistant tumors. A promising approach to better detect and treat these types of cancers may be through
development of agents that target drug resistance biomarkers that associate with cancer stem cells (CSCs).
CSCs make up a small proportion of a tumor but drive tumor aggressiveness and drug resistance. There are
few validated CSC biomarkers, and most are not cancer-specific. Our laboratory is at the forefront of new
biomarker and CSC identification using bacteriophage (phage) display. Peptides and antibody (Ab) fragments
that bind the breast and prostate associated Thomsen-Friedenreich carbohydrate antigen, (TF), the lectin
galectin-3 (gal-3) that binds TF and inhibits immune response, and CD444v6 have been obtained. These
antigens are involved in cell adhesion, angiogenesis, immune regulation, and cell signaling, and are thought to
represent CSC biomarkers. Further, we demonstrated that CD44v6 binds gal-3 through TF interaction,
suggesting this triad may represent a novel target to probe CSCs, tumor growth and immune surveillance.
Both Abs and peptides have been used with mixed success in cancer imaging and therapy. In terms of
Abs their large size can cause immunogenic problems and long distribution times that once radiolabeled often
leads to organ and tissue damage. Conversely, peptides, particularly those from phage display are
usually hydrophobic and often suffer from poor affinity and tumor uptake. Two different tacks will be
employed that overcome these drawbacks. A pretargeted “click” chemistry approach which decouples the
tumor-targeting step from the radioimaging or radiotherapy step can be employed. This pretargeted approach
is based on the rapid and highly specific cycloaddition reaction that occurs between the trans-cyclooctene
(TCO) on the tumor by allowing the unlabeled targeting Ab to circulate and bind the target. Subsequently,
injection of a small molecule radiolabeled probe with rapid pharmacokinetics and high affinity for the
pretargeted Ab, will result in higher tumor to normal tissue uptake ratios compared to direct labeled Abs. The
second tack will be to conjugate small peptides to a nanoparticle for multi-peptide display. Cornell prime dots
(C' dots) are a new and well-characterized nanoparticle platform that offer both multimodal-targeted imaging
and therapy, and multiplexing biomarker interrogation. C' dots are silica core-shell PEG nanoparticles that
exhibit favorable clearance from the blood and are primarily excreted through the kidney overcoming extended
circulation times. The tunable surface chemistries and favorable in vivo pharmacokinetics allow C' dots to
overcome many of the dose limiting toxicities associated with current monomolecular cancer therapeutics.
It is hypothesized that the Ab fragments and peptides that target gal-3/TF/CD44v6, coupled with
pretargeting and C'dot multivalent display, will produce theranostic agents for aggressive prostate (PCa) and
breast cancer (BCa). The objectives of this research are to develop: 1) radioimaging and radiotherapeutic
agents of aggressive PCa and BCa tumors, 2) probes that inhibit tumorigenesis leading to reduced
tumor growth and metastasis, and 3) bifunctional molecular therapeutics that increase tumor immune
response through dual targeting with gal-3 and immune checkpoint inhibitors.
Our work will positively impact VA healthcare in that we are developing new targeting agents for detection
and treatment of cancer that will be well tolerated in vivo. This work will help improve the lives of our Veterans
and coincides with BLR&D general goals and special interests of Women's Health and Genomic Medicine.
侵袭性癌症是美国退伍军人的主要健康问题。虽然大多数癌症
是可以治疗的,与性别有关的癌症,包括乳腺癌和前列腺癌,
当在晚期和/或转移性阶段诊断时通常是致命的。到2020年,这些癌症将占
一般人群每年死亡75,400人,退伍军人的发病率明显较高
人口虽然大多数患者最初对治疗有反应,但他们经常复发并发展为侵袭性和
抗药性肿瘤更好地检测和治疗这些类型的癌症的一种有希望的方法可能是通过
开发靶向与癌症干细胞(CSC)相关的耐药性生物标志物的药物。
CSC占肿瘤的一小部分,但会驱动肿瘤的侵袭性和耐药性。有
一些经验证的CSC生物标志物,并且大多数不是癌症特异性的。我们的实验室是在新的前沿
使用噬菌体(噬菌体)展示的生物标志物和CSC鉴定。肽和抗体(Ab)片段
结合乳腺和前列腺相关的B-F糖抗原(TF),
已经获得了结合TF并抑制免疫应答的半乳糖凝集素-3(gal-3)和CD 444 v6。这些
抗原参与细胞粘附、血管生成、免疫调节和细胞信号传导,并且被认为
代表CSC生物标志物。此外,我们证明了CD 44 v6通过TF相互作用结合gal-3,
提示该三联体可能代表探测CSC、肿瘤生长和免疫监视的新靶点。
抗体和肽两者都已在癌症成像和治疗中取得了混合成功。方面
抗体的大尺寸可导致免疫原性问题和长的分布时间,一旦放射性标记,
导致器官和组织损伤相反,肽,特别是来自噬菌体展示的肽,
通常是疏水性的,并且常常具有差的亲和力和肿瘤摄取。两种不同的策略将是
它克服了这些缺点。一种预先靶向的“点击”化学方法,
可以使用来自放射成像或放射治疗步骤的肿瘤靶向步骤。这种有针对性的方法
是基于快速和高度特异性的环加成反应,发生之间的反式环辛烯
(TCO)通过允许未标记的靶向Ab循环并结合靶点,随后,委员会注意到,
注射具有快速药代动力学和高亲和力的小分子放射性标记探针
与直接标记的Ab相比,预先靶向的Ab将导致更高的肿瘤与正常组织摄取比率。的
第二种方法是将小肽结合到纳米颗粒上用于多肽展示。康奈尔素点
(C' dots)是一种新的和良好表征的纳米颗粒平台,
和治疗,以及多路生物标记询问。C'点是二氧化硅核-壳PEG纳米颗粒,
表现出良好的血液清除率,主要通过肾脏排泄,
流通时报可调的表面化学和有利的体内药代动力学允许C'点
克服了与当前单分子癌症治疗剂相关的许多剂量限制毒性。
假设靶向gal-3/TF/CD 44 v6的Ab片段和肽与
预靶向和C 'dot多价展示将产生用于侵袭性前列腺(PCa)的治疗诊断剂,
乳腺癌(BCa)。本研究的目标是:1)放射成像和放射学
侵袭性PCa和BCa肿瘤的试剂,2)抑制肿瘤发生的探针,
肿瘤生长和转移,以及3)增加肿瘤免疫的双功能分子治疗剂
通过与gal-3和免疫检查点抑制剂的双重靶向反应。
我们的工作将对VA医疗保健产生积极影响,因为我们正在开发新的靶向检测剂
以及在体内耐受良好的癌症治疗。这项工作将有助于改善我们退伍军人的生活
与BLR&D的总体目标和妇女健康与基因组医学的特殊利益相一致。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SUSAN L DEUTSCHER其他文献
SUSAN L DEUTSCHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SUSAN L DEUTSCHER', 18)}}的其他基金
Targeting TF/CD44v6 for In Vivo Nano-generated alpha-therapy of Ovarian Cancer
靶向 TF/CD44v6 用于卵巢癌体内纳米α疗法
- 批准号:
8769083 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Targeting TF/CD44v6 for In Vivo Nano-generated alpha-therapy of Ovarian Cancer
靶向 TF/CD44v6 体内纳米α疗法治疗卵巢癌
- 批准号:
8878206 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Multivalent Nanophage Engineered as Dual Receptor Cancer Theranostic Agents.
多价纳米噬菌体被设计为双受体癌症治疗剂。
- 批准号:
8569062 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Phage Display for Improved Peptide-Based Tumor Targeting and Imaging Agents
用于改进基于肽的肿瘤靶向和成像剂的噬菌体展示
- 批准号:
10343781 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Phage Display for Improved Peptide-based Tumor Targeting and Imaging Agents
用于改进基于肽的肿瘤靶向和成像剂的噬菌体展示
- 批准号:
8263685 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Phage Display for Improved Peptide-Based Tumor Targeting and Imaging Agents
用于改进基于肽的肿瘤靶向和成像剂的噬菌体展示
- 批准号:
10554256 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Phage Display for Improved Peptide-based Tumor Targeting and Imaging Agents
用于改进基于肽的肿瘤靶向和成像剂的噬菌体展示
- 批准号:
8398936 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Phage Display for Improved Peptide-Based Tumor Targeting and Imaging Agents
用于改进基于肽的肿瘤靶向和成像剂的噬菌体展示
- 批准号:
9236073 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Phage Display for Improved Peptide-based Tumor Targeting and Imaging Agents
用于改进基于肽的肿瘤靶向和成像剂的噬菌体展示
- 批准号:
8138754 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Improved Peptide-based Tumor Targeting Agents Using Phage Display
使用噬菌体展示改进基于肽的肿瘤靶向剂
- 批准号:
7775087 - 财政年份:2009
- 资助金额:
-- - 项目类别:
相似海外基金
Rationally guided discovery platform for monoclonal antibodies against carbohydrate antigens using virus-like particle conjugate immunization and high throughput selection
使用病毒样颗粒缀合物免疫和高通量选择的合理引导的针对碳水化合物抗原的单克隆抗体的发现平台
- 批准号:
10574738 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Assessing the role of liver stage antigens-specific antibodies against Plasmodium falciparum liver stage infection
评估肝期抗原特异性抗体对抗恶性疟原虫肝期感染的作用
- 批准号:
10392870 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
生成最佳非 HRP2 疟疾诊断抗原的特异性抗体
- 批准号:
10092930 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
生成最佳非 HRP2 疟疾诊断抗原的特异性抗体
- 批准号:
9896170 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Interrogation of cell surface antigens on B lineage cells using structurally unique variable lymphocyte receptor antibodies of the evolutionarily distant sea lamprey
使用进化遥远的海七鳃鳗结构独特的可变淋巴细胞受体抗体询问 B 谱系细胞上的细胞表面抗原
- 批准号:
433456 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Operating Grants
Investigations of interactions between various natural antibodies and food-derived antigens
研究各种天然抗体与食物源性抗原之间的相互作用
- 批准号:
19K15765 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identifying Kawasaki Disease-Specific Antibodies and Antigens
识别川崎病特异性抗体和抗原
- 批准号:
9932769 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Novel Scoring Methods for Interactions between Antibodies and Antigens
抗体和抗原之间相互作用的新评分方法
- 批准号:
BB/P504713/1 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Training Grant
Novel Scoring Methods for Interactions between Antibodies and Antigens
抗体和抗原之间相互作用的新评分方法
- 批准号:
1932904 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Studentship
SBIR Phase II: Automated Design Methods of Antibodies Directed to Protein and Carbohydrate Antigens
SBIR II 期:针对蛋白质和碳水化合物抗原的抗体的自动化设计方法
- 批准号:
1632399 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Standard Grant